AchilleS Vaccines

AchilleS Vaccines—now known as Contraria Biotech—is an Italian biotechnology company focused on developing innovative vaccines and monoclonal antibodies targeting major global health threats such as antibiotic resistance, emerging infectious diseases, malaria, meningococcal disease, gonorrhea, typhoid/paratyphoid fever, and COVID‑19. The company has received significant EU funding to advance its pipeline—including €11 million from the EU Malaria Fund—and collaborates with leading academic institutions like the University of Cambridge. Its platforms include mOMV-based vaccines/antibodies with demonstrated high immunogenicity in humans. As of mid–2021 to mid–2024 its lead programs are preclinical or entering early clinical stages.